57
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Repurposing mitochondria from ATP production to ROS generation drives a pro-inflammatory phenotype in macrophages that depends on succinate oxidation by complex II

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Activated macrophages undergo metabolic reprogramming which drives their pro-inflammatory phenotype, but the mechanistic basis for this remains obscure. Here we demonstrate that upon lipopolysaccharide (LPS) stimulation macrophages shift from producing ATP by oxidative phosphorylation to glycolysis, while also increasing succinate levels. We show that increased mitochondrial oxidation of succinate via succinate dehydrogenase (SDH) and an elevation of mitochondrial membrane potential combine to drive mitochondrial ROS production. RNA sequencing reveals that this combination induces a pro-inflammatory gene expression profile, while an inhibitor of succinate oxidation, dimethyl malonate (DMM), promotes an anti-inflammatory outcome. Blocking ROS production with rotenone, by uncoupling mitochondria, or by expressing the alternative oxidase (AOX) inhibits this inflammatory phenotype, with AOX protecting mice from LPS lethality. The metabolic alterations that occur upon activation of macrophages therefore repurpose mitochondria from ATP synthesis to ROS production in order to promote a pro-inflammatory state.

          Related collections

          Author and article information

          Journal
          0413066
          2830
          Cell
          Cell
          Cell
          0092-8674
          1097-4172
          19 March 2018
          22 September 2016
          06 October 2016
          22 March 2018
          : 167
          : 2
          : 457-470.e13
          Affiliations
          [1 ]School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Ireland
          [2 ]MRC Mitochondrial Biology Unit, Hills Road, Cambridge CB2 0XY, UK
          [3 ]MRC Cancer Unit, University of Cambridge, Hutchison/MRC Research Centre, Box 197, Cambridge Biomedical Campus, Cambridge, CB2 0XZ
          [4 ]Center for Computational and Integrative Biology, Massachusetts General Hospital and, Harvard Medical School, Boston, Massachusetts, USA
          [5 ]Gastrointestinal Unit, Center for the Study of Inflammatory Bowel Disease, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
          [6 ]Department of Veterinary Medicine, University of Cambridge, Madingley Road, Cambridge, UK
          [7 ]Cancer Metabolism Research Unit, Cancer Research UK, Beatson Institute, Garscube Estate, Switchback Road, Bearsden, Glasgow, G61 1BD
          [8 ]Institute of Biotechnology, P.O. Box 56, 00014 University of Helsinki, Finland and, BioMediTech and Tampere University Hospital, University of Tampere, FI-33014, Finland
          [9 ]Max-Planck-Institute for Heart and Lung Research, Ludwigstrasse 43, 61231 Bad Nauheim, Germany
          Author notes
          [^]

          These authors jointly supervised this work

          [+]

          Current address: GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire, UK

          Article
          PMC5863951 PMC5863951 5863951 ems76743
          10.1016/j.cell.2016.08.064
          5863951
          27667687
          2e67fd74-f080-464d-b466-eb02cd4a944c
          History
          Categories
          Article

          Comments

          Comment on this article